ストックスクリーナーアプリを入手
3.61
46.15%
1.14
前日終値:
$2.47
開ける：
$2.61
24時間の取引高:
35.65M
Relative Volume:
10.74
時価総額：
$330.19M
収益：
-
当期純損益:
$-67.68M
株価収益率:
-2.1747
EPS:
-1.66
ネットキャッシュフロー:
$-54.24M
1週間 パフォーマンス:
+46.15%
1か月 パフォーマンス:
+54.27%
6か月 パフォーマンス:
+173.48%
1年 パフォーマンス:
+1.69%
1日の値動き範囲:
$2.56
$3.67
1週間の範囲:
$2.39
$3.67
52週間の値動き範囲:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
CABA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.61 | 225.92M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 再開されました | Jefferies | Buy |
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-02-05 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 開始されました | William Blair | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | Stifel | Buy |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock? - MSN
Can Cabaletta Bio Inc. hit a new high this monthJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025Trade Entry Report & Verified Swing Trading Watchlist - newser.com
Cabaletta Bio Stock Climbs Amid Positive Clinical Developments - StocksToTrade
Cabaletta Bio Poised for Growth Amid Positive Clinical Data Releases - timothysykes.com
Cabaletta Bio (NASDAQ:CABA) Price Target Raised to $30.00 - MarketBeat
Tools to assess Cabaletta Bio Inc.’s risk profileJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Weekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com
Will Cabaletta Bio Inc. see short term momentum2025 Breakouts & Breakdowns & Technical Pattern Based Signals - newser.com
CABA Stock: Cantor Fitzgerald Raises Price Target to $30, Mainta - GuruFocus
How Cabaletta Bio Inc. stock reacts to bond yieldsJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Comparing Cabaletta Bio Inc. in custom built stock radars2025 Market Trends & Scalable Portfolio Growth Methods - newser.com
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials - Insider Monkey
Is Cabaletta Bio Inc. stock attractive for long term wealth buildingEarnings Miss & Consistent Profit Trading Strategies - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsJuly 2025 Update & Safe Entry Point Alerts - newser.com
Applying sector rotation models to Cabaletta Bio Inc.July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Can Cabaletta Bio Inc. stock maintain operating marginsAnalyst Upgrade & Safe Investment Capital Preservation Plans - newser.com
10 Best Stocks Under $3 to Invest In - Insider Monkey
Visualizing Cabaletta Bio Inc. stock with heatmaps2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Cabaletta Bio Updates on CD19-CAR T Therapy Progress - TipRanks
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
How Cabaletta Bio Inc. stock benefits from strong dollarPortfolio Gains Summary & Reliable Trade Execution Plans - Fundação Cultural do Pará
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial - BioSpace
Cabaletta Bio stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Philippines
How Cabaletta Bio Inc. stock compares to growth peers2025 Technical Patterns & AI Powered Market Entry Strategies - Fundação Cultural do Pará
What makes Cabaletta Bio Inc. stock attractive to growth fundsDollar Strength & High Accuracy Trade Alerts - Fundação Cultural do Pará
Entry Recap: Can Cabaletta Bio Inc. stock rebound after recent weaknessJuly 2025 Institutional & Technical Buy Zone Confirmations - Fundação Cultural do Pará
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):